These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1065 related articles for article (PubMed ID: 24011636)

  • 1. New pharmacological options for treating advanced Parkinson's disease.
    Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
    Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate : a treatment for Parkinson's disease?
    Devos D; Moreau C; Delval A; Dujardin K; Defebvre L; Bordet R
    CNS Drugs; 2013 Jan; 27(1):1-14. PubMed ID: 23160937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological hypotheses and therapeutic strategies for gait disorders in Parkinson's disease].
    Devos D; Bordet R; Defebvre L
    Rev Neurol (Paris); 2010 Feb; 166(2):168-77. PubMed ID: 19811797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.
    Moreau C; Delval A; Defebvre L; Dujardin K; Duhamel A; Petyt G; Vuillaume I; Corvol JC; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Sablonniere B; Azulay JP; Tison F; Rascol O; Vidailhet M; Destée A; Bloem BR; Bordet R; Devos D;
    Lancet Neurol; 2012 Jul; 11(7):589-96. PubMed ID: 22658702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
    Thobois S; Ardouin C; Lhommée E; Klinger H; Lagrange C; Xie J; Fraix V; Coelho Braga MC; Hassani R; Kistner A; Juphard A; Seigneuret E; Chabardes S; Mertens P; Polo G; Reilhac A; Costes N; LeBars D; Savasta M; Tremblay L; Quesada JL; Bosson JL; Benabid AL; Broussolle E; Pollak P; Krack P
    Brain; 2010 Apr; 133(Pt 4):1111-27. PubMed ID: 20237128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
    Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
    Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease.
    Devos D; Defebvre L; Bordet R
    Fundam Clin Pharmacol; 2010 Aug; 24(4):407-21. PubMed ID: 20163480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.
    Merola A; Zibetti M; Angrisano S; Rizzi L; Ricchi V; Artusi CA; Lanotte M; Rizzone MG; Lopiano L
    Brain; 2011 Jul; 134(Pt 7):2074-84. PubMed ID: 21666262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials.
    Kalia LV; Brotchie JM; Fox SH
    Mov Disord; 2013 Feb; 28(2):131-44. PubMed ID: 23225267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significant improvement of motor symptoms by deep brain stimulation of bilateral subthalamic nucleus in patients with moderate or advanced Parkinson's disease].
    Chen J; Liu JL; Chen X; Qian H; Xian WB; Zhou HY; Liu YM; Ye XF; Zheng YF; Zhang SL; Chen L; Li JR; Liu ZL; Pei Z
    Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(5):291-5. PubMed ID: 21419000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
    Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
    Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions.
    Ramirez-Zamora A; Molho E
    Expert Rev Neurother; 2014 Jan; 14(1):93-103. PubMed ID: 24328720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
    Yamada K; Goto S; Hamasaki T; Kuratsu JI
    Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Milestones in Parkinson's disease therapeutics.
    Rascol O; Lozano A; Stern M; Poewe W
    Mov Disord; 2011 May; 26(6):1072-82. PubMed ID: 21626552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
    Devos D; Krystkowiak P; Clement F; Dujardin K; Cottencin O; Waucquier N; Ajebbar K; Thielemans B; Kroumova M; Duhamel A; Destée A; Bordet R; Defebvre L
    J Neurol Neurosurg Psychiatry; 2007 May; 78(5):470-5. PubMed ID: 17098845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease.
    Wolters ECh
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S18-23. PubMed ID: 17702631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.
    Thobois S; Lhommée E; Klinger H; Ardouin C; Schmitt E; Bichon A; Kistner A; Castrioto A; Xie J; Fraix V; Pelissier P; Chabardes S; Mertens P; Quesada JL; Bosson JL; Pollak P; Broussolle E; Krack P
    Brain; 2013 May; 136(Pt 5):1568-77. PubMed ID: 23543483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.